What is Sudeep Pharma Ltd (SUDEEPPHRM) share price return in the past 10 years?

Data is not available for this company

What is the share price of Sudeep Pharma Ltd (SUDEEPPHRM)?

Company share prices are keep on changing according to the market conditions. The current trading price of Sudeep Pharma Ltd (SUDEEPPHRM) on 02-Jul-2026 16:59:59 at 16:59 is 856.50.

What is the P/E ratio of Sudeep Pharma?

The latest standalone P/E ratio of Sudeep Pharma as of 02-Jul-2026 is 89.92.

What is the P/B ratio of Sudeep Pharma Ltd (SUDEEPPHRM)?

The latest standalone P/B ratio of Sudeep Pharma Ltd (SUDEEPPHRM) as of 02-Jul-2026 is 12.31.

What is the 52-week high and low of Sudeep Pharma Ltd (SUDEEPPHRM)?

The 52-week high of Sudeep Pharma Ltd (SUDEEPPHRM) is Rs. 883.20 and the 52-week low is Rs. 524.95.

Sudeep Pharma Ltd (SUDEEPPHRM) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Sudeep Pharma Ltd (SUDEEPPHRM)
Brand: Sudeep Pharma

Key Metrics

Valuation Multiples

Market Cap

₹9,674 Cr.

Current Price

₹856.5

52-Week Low / High

₹525 / 883

TTM EPS

₹9.5

TTM Sales

₹339 Cr.

Book Value per Share

₹69.6

P/E Ratio

89.92

Higher than its 5-year historical median

Industry PE

49.2

Price to Book (P/B)

12.31

Higher than its 5-year historical median

Price to Sales (P/S)

28.58

Higher than its 5-year historical median

EV/EBITDA

61.34

Higher than its 5-year historical median

Dividend Yield

Profitability Efficiency

Return on Equity (ROE)

25.12%

Outperforms industry median

Return on Capital Employed (ROCE)

28.72%

Outperforms industry median

Return on Assets (ROA)

18.16%

Operating Profit Margin

37.3%

Net Profit Margin

26.84%

Gross Profit Margin

38%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

3.77%

Operating Profit Growth (1 Year)

Slowing versus 3-year growth rate

-0.08%

Net Profit Growth (1 Year)

Slowing versus 3-year growth rate

-2.38%

Asset Quality

Promoter Holding

76.15%

Pledged shares (%) of Promoter's holding (%)

0.00%

Reserves

₹775 Cr.

Equity

₹11.3 Cr.

Face Value

₹1

All Time Low / High

₹524.95 / 883.20

Sudeep Pharma stock performance

Key Ratios

Check Before You Invest

Quality

Very Good

Check detailed performance

Valuation

Overvalued

Check Valuation charts

Price Trend

Strong

Check Price chart

Q.1 Is Sudeep Pharma Ltd a good quality company?

Sudeep Pharma Ltd is a good quality company, based on a consistently good multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

How does Sudeep Pharma Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Sudeep Pharma Ltd vs industry peers?

Sudeep Pharma Ltd revenue CAGR is 23.73%, compared to the industry median CAGR of 5.35%, indicating faster growth and gaining its market share.

Q.1 Promoter shareholding and pledge status of Sudeep Pharma Ltd?

Promoters hold 76.15% of the Sudeep Pharma Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Stock return of Sudeep Pharma Ltd over the last decade?

Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	22.1%	29.1%	26%	28.9%	29.8%	37%	37.1%	34.6%	38.9%	28.7%	-
Value Creation Index ⓘ	0.6	1.2	0.9	1.1	1.2	1.7	1.8	1.6	1.9	1.1	-
Growth Parameters ⓘ
Sales ⓘ	44.5	50	58.7	89.1	123	218	345	404	344	357	339
Sales YoY Gr.	-	12.5%	17.4%	51.7%	38.1%	77.1%	58.3%	17.1%	-14.9%	3.8%	-
Adj EPS ⓘ	0.5	0.7	1	1.1	1.8	3.4	5	6.3	9.8	9.5	9.5
YoY Gr.	-	58.7%	30.1%	17.9%	60.7%	90%	46.2%	25%	56.8%	-3.4%	-
BVPS (₹) ⓘ	3.5	4.3	5.3	6.5	8.3	11.9	17.3	24.4	34.5	44	69.6
Adj Net Profit ⓘ	4.5	7.1	9.2	10.9	17.4	33.2	48.6	60.6	95.1	92.1	107
Cash Flow from Ops. ⓘ	10.4	3.7	13.4	12.9	9.9	35.8	-5.3	42.3	59.1	59.2	-
Debt/CF from Ops. ⓘ	0.2	1.1	0.3	0.6	2	0.9	-13.6	1.7	1	2	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	26%	23.7%	1.1%	3.8%
Adj EPS ⓘ	39.9%	39.4%	23.7%	-3.4%
BVPSⓘ	32.4%	39.5%	36.4%	27.7%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	16.4	18.7	19.8	19	24.2	33.7	34.2	29.9	33.3	24.1	16.8
Op. Profit Mgn % ⓘ	17	23.9	21.6	19.7	20.6	21	19.8	21.9	38.8	37.3	37.1
Net Profit Mgn % ⓘ	10.1	14.2	15.7	12.2	14.2	15.2	14.1	15	27.7	25.8	31.8
Debt to Equity ⓘ	0.1	0.1	0.1	0.1	0.3	0.3	0.4	0.3	0.2	0.3	0
Working Cap Days ⓘ	134	120	131	113	129	120	143	205	292	311	274
Cash Conv. Cycle ⓘ	48	46	59	57	70	67	91	111	123	155	171

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	44	50	59	89	123	218	345	404	344	357
Operating Expenses ⓘ +	37	38	46	72	98	172	277	316	211	224
Manufacturing Costs	8	5	7	10	12	13	19	22	27	31
Material Costs	20	21	25	32	45	83	135	175	126	119
Employee Cost	4	4	6	7	9	11	14	14	20	26
Other Costs ⓘ	6	7	9	23	31	64	109	106	37	48
Operating Profit ⓘ	7	12	13	18	25	46	68	88	133	133
Operating Profit Margin (%)	16.9%	23.8%	21.5%	19.7%	20.6%	21.0%	19.8%	21.8%	38.7%	37.2%
Other Income ⓘ +	1	1	2	3	3	4	8	11	8	8
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	1	0	0	1	1	1	2	4	4	6
Depreciation ⓘ	1	1	2	2	3	4	4	5	5	6
Profit Before Tax ⓘ	7	12	13	18	25	45	70	91	132	129
Tax ⓘ	2	4	3	6	7	10	18	24	34	34
Profit After Tax	5	7	9	12	18	35	52	67	98	96
PAT Margin (%)	10.7%	14.9%	16.1%	13.2%	14.7%	16.1%	15.2%	16.6%	28.5%	26.8%
Adjusted EPS (₹)	0.5	0.8	1.0	1.2	1.9	3.6	5.4	6.9	10.1	9.9
Dividend Payout Ratio (%)	18.10%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Valuation of Sudeep Pharma - Standalone

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	34	42	51	63	81	116	168	237	335	430
Share Capital ⓘ	1	1	1	1	1	1	1	1	1	12
Reserves ⓘ	33	40	50	61	80	115	167	235	333	418
Debt +	2	4	4	7	17	31	73	70	51	111
Long Term Debt	0	0	1	1	8	14	17	11	5	36
Short Term Debt	2	4	2	6	9	17	55	59	46	75
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	3	4	6	6	9	17	24	39	34	36
Others Liabilities ⓘ	3	4	5	16	24	50	68	70	30	27
Total Liabilities ⓘ	42	54	66	93	131	214	333	416	451	604
Fixed Assets
Net Fixed Assets ⓘ +	25	26	32	54	60	68	120	81	96	105
Gross Block	30	32	39	63	72	83	139	86	106	120
Accumulated Depreciation	5	6	7	9	12	16	19	4	10	15
CWIP ⓘ	0	1	9	1	8	23	4	26	43	88
Investments ⓘ	1	4	1	0	6	24	15	19	29	32
Inventories	4	9	4	8	9	15	26	52	45	65
Trade Receivables	5	7	13	18	30	58	123	126	141	162
Cash Equivalents	1	1	3	4	4	8	15	6	9	45
Others Assets ⓘ	6	6	4	8	13	17	30	105	87	107
Total Assets ⓘ	42	54	66	93	131	214	333	416	451	604

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	10	4	13	13	10	36	-5	42	59	59
PBT ⓘ	7	12	13	18	25	45	70	91	132	129
Adjustment ⓘ	2	1	2	3	4	4	5	13	8	9
Changes in Working Capital ⓘ	4	-6	2	-4	-13	-3	-64	-39	-45	-50
Tax Paid ⓘ	-2	-3	-3	-4	-6	-11	-17	-22	-36	-30
Cash Flow From Investing Activity ⓘ +	-7	-6	-12	-15	-22	-45	-28	-41	-41	-92
Capex	-11	-2	-8	-24	-9	-12	-56	-38	-32	-61
Net Investments	-1	-3	3	1	-6	0	0	-3	3	-15
Others ⓘ	6	-0	-8	8	-7	-33	28	0	-12	-16
Cash Flow From Financing Activity ⓘ +	-3	2	-0	3	12	13	40	-10	-16	54
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-5	0	2	1	10	14	42	-6	-8	32
Interest Paid ⓘ	-1	-0	-0	-1	-1	-1	-2	-4	-3	-4
Dividend Paid ⓘ	-1	0	0	0	0	0	0	0	0	0
Others ⓘ	3	2	-2	3	4	-0	-0	-0	-5	27
Net Cash Flow ⓘ	1	0	1	2	-0	4	7	-9	2	22

Financial Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	17.36	19.58	20.3	20.6	25.08	35.54	36.81	33.16	34.32	25.12
ROCE (%)	22.08	29.1	26.03	28.93	29.75	37.02	37.14	34.56	38.9	28.72
Asset Turnover Ratio	1.15	1.14	1.01	1.13	1.1	1.26	1.26	1.08	0.79	0.68
PAT to CFO Conversion(x)	2	0.57	1.44	1.08	0.56	1.03	-0.1	0.63	0.6	0.61
Working Capital Days
Receivable Days	51.30	39.10	60.20	63.50	71.80	74.10	95.80	112.60	142	155.20
Inventory Days	40.30	40.80	38.60	25.60	26.50	20.60	21.90	35.60	51.90	56.30
Payable Days	79.60	58	70.90	70.10	60.80	55.70	55.40	66.30	106.40	108

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Sudeep Pharma Ltd FAQs

The current trading price of Sudeep Pharma on 02-Jul-2026 16:59 is ₹856.5.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jul-2026 the market cap of Sudeep Pharma stood at ₹9,674.1 Cr

The latest P/E ratio of Sudeep Pharma as of 01-Jul-2026 is 89.92.

The latest P/B ratio of Sudeep Pharma as of 01-Jul-2026 is 12.31.

The 52-week high of Sudeep Pharma is ₹883.2 and the 52-week low is ₹525.0.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sudeep Pharma is ₹339 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Sudeep Pharma Ltd is a good quality company.

The key valuation ratios of Sudeep Pharma Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Sudeep Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

About Sudeep Pharma Ltd

Sudeep Pharma was incorporated as ‘Sudeep Pharma Private Limited’ as a private limited company on December 21, 1989 in Gujarat at Ahmedabad. Thereafter, the company was converted into a public limited company and the name of the company was accordingly changed to ‘Sudeep Pharma Limited’. The company was subsequently converted back to a private limited company and the name of the company was accordingly changed from ‘Sudeep Pharma Limited’ to ‘Sudeep Pharma Private Limited’. Further, pursuant to the special resolution passed by the shareholders dated August 17, 2024 and the company was converted into a public limited company and consequently, the name of the company was changed to ‘Sudeep Pharma Limited’.

The company is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries. It is one of the largest producers of food-grade iron phosphate for infant nutrition, clinical nutrition, and the food and beverage sectors. It is one of the largest exporters of mineral ingredients for pharmaceutical, food and nutrition industries from India to global markets. It is one of few companies with certification of suitability issued by the Council of Europe (CEP) and written confirmation certification for sale of calcium carbonate as an active pharmaceutical ingredient (API) in the European Union.

It leverages its inhouse developed technologies for processes such as encapsulation, spray drying, granulation, trituration, liposomal preparations and blending in an effort to drive innovation in its operations. It has established a presence in both, domestic and international markets.

Business area of the company

The company along with its subsidiary companies is engaged in business of manufacturing of excipients and specialty ingredients for the pharmaceutical, food and nutrition industries and is dedicated to contributing to the global healthcare ecosystem by providing excipients and specialty ingredients. It develops solutions that enhance vitality, functionality, and efficiency in consumer products.

Business verticals of the company

Pharmaceutical, Food and Nutrition Business - The company provides mineral-based ingredients for a wide range of applications in the pharmaceutical, food, and nutrition industries. Its offering includes essential mineral salts such as calcium, zinc, iron, potassium, magnesium, sodium, simethicone and copper.
Specialty Ingredients Business - The company develops and manufactures innovative specialty ingredients, which serve various sectors such as food, nutrition, pharmaceuticals, and health supplement. Its offering includes Micro-nutrient Premixes, Liposomal Ingredients, Encapsulated Ingredients, Spray Dried Ingredients and Granulated Ingredients.
Triturates - The company’s Tritunova line of triturated nutrients provides a uniform micronutrient blend on a carrier substrate, ensuring consistent distribution of active nutrients when incorporated into final products.

Awards, accreditations and recognition

2008: ‘Certificate of Appreciation for the years 2008-09 in the Exports category of Small Scale Industries’ awarded by Pharmexcil to the company.
2016: ‘Appreciation for contribution as a Business Partner’ awarded by Abbott to the company.
2021: ‘Certificate of Membership’ awarded by PRM Industries Association to the company’s Indian material subsidiary, Sudeep Nutrition Private Limited.
2021: ‘Appreciation for contribution during COVID’ awarded by Abbott to the company.
2023: ‘Certificate of Appreciation’ awarded by the Federation of Telangana Chambers of Commerce and Industry (FTCCI), Hyderabad to the company’s Indian material subsidiary, Sudeep Nutrition Private Limited.
2023: ‘Excellence Award for Excellence in Innovative Ingredients Manufacturing’ awarded by ASSOCHAM to the company’s Indian material subsidiary, Sudeep Nutrition Private Limited.
2023: ‘Suppliers Summit 2023 Award’ awarded by Herbalife to the company’s Indian material subsidiary, Sudeep Nutrition Private Limited.
2023: ‘Global Indian MSME of the Year in Manufacturing’ awarded by The Economic Times to the company at ‘The Economic Times MSME Awards 2023’.
2023: ‘Customer Centric Business Partner’ awarded by Abbott to the company.
2024 ‘FRK Manufacturing Excellence Award’ awarded by Millers for Nutrition to the company’s Indian material subsidiary, Sudeep Nutrition Private Limited.

History and milestones

1989: Incorporation of the company.
2017: The company obtained USFDA certification for mineral based ingredients.
2020: Incorporation of the company’s subsidiary, Sudeep Pharma USA Inc.
2021: Incorporation of the company’s subsidiary, Sudeep Nutrition Private Limited.
2022: The company obtained written confirmation certification for sale of calcium carbonate as an active pharmaceutical ingredient.
2023: Incorporation of the company’s subsidiary, Sudeep Pharma B.V.
2024: Incorporation of the company’s subsidiary, Sudeep Advanced Materials Private Limited.
2024: The company’s subsidiary, Sudeep Nutrition Private Limited, introduced liposomal encapsulation of nutrients for enhanced absorption.
2025: Acquisition of the company’s step-down subsidiary, Nutrition Supplies and Services (Ireland) Limited.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Sudeep Pharma Ltd (SUDEEPPHRM)

Sudeep Pharma Ltd (SUDEEPPHRM)

Sudeep Pharma stock performance

Check Before You Invest

Quality

Valuation

Price Trend

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Profit And Loss

Valuation of Sudeep Pharma - Standalone

Price Calculator

Price Chart

Price to Earnings

Price to Sales

Price to Book

EV to EBITDA

Dividend History

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

Balance Sheet

Equity and Liabilities

Fixed Assets

Cash Flow

Financial Ratio

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Sudeep Pharma Ltd FAQs

What is the share price of Sudeep Pharma?

What is the market cap of Sudeep Pharma?

What is the P/E ratio of Sudeep Pharma?

What is the P/B ratio of Sudeep Pharma?

What is the 52-week high and low of Sudeep Pharma?

What is the TTM revenue of Sudeep Pharma?

Is Sudeep Pharma Ltd a good quality company?

Is Sudeep Pharma Ltd undervalued or overvalued?

Is Sudeep Pharma Ltd a good buy now?

About Sudeep Pharma Ltd

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.